[12] Patent
[11] Patent No.:GC0007651  
[45] Date of Publishing the Grant of the Patent: 30/Apr /2018                48/2018  
Number of the Decision to Grant the Patent:2018/126500
Date of the Decision to Grant the Patent:25/Apr/2018

[21] Application No.:GC 2014-26616

[22] Filing Date:6/3/2014

[30] Priority:

[33] State [32] Priority date [31] Priority No.
EP
7/3/2013
13158233.0

[72] Inventors:1- Uwe GRETHER،2- Matthias NETTEKOVEN،3- Atsushi KIMBARA،4- Stephan ROEVER،5- Mark ROGERS-EVANS،6- Tanja SCHULZ-GASCH،7- Fabienne RICKLIN

[73] Owner: F. Hoffmann - La Roche AG, 124 Grenzacherstrasse , Basle , Switzerland

[74] Agent: Kadasa Law Firm

  

 

  

[51]IPC:
Int. Cl.: C07D 471/04, 473/04, 487/04 (2006.01)

[56] Cited Documents:

-WO 2006047516 A2 (IRM LLC [US]; LIU HONG [US]; HE XIAOHUI [US]; CHOI HA-SOON [US]; YANG) 4 May 2006
-WO 0158869 A2 (SQUIBB BRISTOL MYERS CO [US]; LEFTHERIS KATERINA [US]; ZHAO RULIN [US]) 16 August 2001
 
Examiner: PH. Bashair Z. AlEnizi

[54] NOVEL PYRAZOL DERIVATIVES
[57] Abstract: The invention relates to a compound of formula (I) (I)wherein A1 to A3 and R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
No. of claims: 18


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.